Table 1.
Day | −3 or −2 | 0 | 3 | 7 (±1) | 15 (±3) | 30 (±5) | 60 (±7) | 90 (±7) |
---|---|---|---|---|---|---|---|---|
Recruitment |
√ |
|
|
|
|
|
|
|
Informed consent |
√ |
|
|
|
|
|
|
|
Selection criteria |
√ |
|
|
|
|
|
|
|
Medical history |
√ |
|
|
|
|
|
|
|
Physical examination |
√ |
|
|
|
|
|
|
√ |
Blood samples for pharmacogenetics |
√ |
|
|
|
|
|
|
|
Randomization |
√ |
|
|
|
|
|
|
|
Acenocoumarol dosing (initiation/adjustment)a |
|
√ |
√ |
√ |
√ |
√ |
√ |
√ |
INR determination |
|
√ |
√ |
√ |
√ |
√ |
√ |
√ |
Evaluation of side effects | √ | √ | √ | √ | √ | √ | √ |
aIn order to perform appropriate dose adjustments, additional visits can be scheduled as needed, at the discretion of the clinical researcher.